Faculty of Medicine and Health Science, UIN Maulana Malik Ibrahim, Indonesia
*Corresponding Author:
Yahya Muhammed Bah, Department of Sociology, School of Arts and Sciences, University of the Gambia, Banjul, the Gambia, West Africa
Citation: Yahya Muhammed Bah, (2022) Part Of Vitamin D in Systemic Lupus Erythematosus Rate and Disturbance: The Systematic Review and Metaanalysis Journal of Clinical Case Reports and Studies 3(6); DOI: 10.31579/2690-8808/112
Introduction: Vitamin D is one of the most bunches of sterols; playing a critical part in phospho-calcic digestion system. The change of 7-dehydrocholesterol to pre- vitamin D3 within the skin, through sun oriented bright B radiation, is the most source of vitamin D. Since lupus patients are more often than not photosensitive, the chance of creating vitamin D lack in is tall in this populace. In spite of the fact that confirmations appeared the intention between systemic lupus erythematosus (SLE) and vitamin D through which SLE can lead to lower vitamin D levels, it is additionally imperative to consider the plausibility that vitamin D insufficiency may have a causative part in SLE etiology. This paper analyzes existing information from different thinks about to highlight the part of vitamin D lack in SLE event and disturbance and the plausible adequacy of vitamin D supplementation on SLE patients.
Method: This study using systematic review that search using keyword Vitamin D and Systemic Lupus Erythematosus in PubMed, Google Scholar and Science Direct.
Result: After final screening the author analysize 4 articles. As in methods, the author summarize 4 articles.
Conclusion: Confirmations appear that vitamin D plays an critical part within the pathogenesis and movement of SLE and vitamin D supplementation appears to improve incendiary and hemostatic markers; so, can progress clinical ensuing.
Introduction
Systemic lupus erythematosus or SLE, a systemic immune system malady, can cause persistent irritation and harm in a few tissues and organs [1]. Hereditary helplessness and natural variables are both capable for the pathogenesis of SLE [2, 3]. Vitamin D lack is one of such variables [4]. Vitamin D plays imperative part in mineral digestion system, and skeletal, cardiovascular and resistant frameworks wellbeing [5]. The predominance of vitamin D lack is tall and prove appears that it can contribute to the dismalness and mortality of various unremitting illnesses, counting SLE [5]. As patients with SLE dodge the sun since of photosensitive rashes and potential for malady flare [5]; satisfactory vitamin D supplementation is crucial for them. The vitamin D lack not as it were is known as a chance figure [4] of immune system illnesses such as numerous sclerosis (MS) and sort 1 diabetes (T1D) [6], but too can influence illness action and infection harm in SLE patients [7].
Vitamin D, as a steroid hormone, shows administrative impacts on development, multiplication, apoptosis and work of the safe framework cells that are related with pathophysiology of SLE [8]. Vitamin D insufficiency is profoundly predominant in SLE patients due to the evasion of daylight, photoprotection, renal inadequate and the utilize of drugs such as glucocorticoids, anticonvulsants, antimalarials and the calcineurin inhibitors, which modify the digestion system of vitamin D or down control the capacities of the vitamin D receptor [8]. Kamen et al. [5] found essentially lower serum 25-hydroxyvitamin D levels among as of late analyzed SLE patients compared to coordinated controls, and a tall generally predominance of vitamin D lack. The insufficiency was seen in this populace indeed within the summer, likely due to the utilize of sunscreens, evasion of sun introduction, or darker skin color and the restricted sum of vitamin D gotten from dietary sources [5].
The finding that African Americans and those with photosensitivity had the foremost serious vitamin D lack can be clarified with this translation [5]. As found by Borba et al. [9] the level of 25OHD and 1,25(OH)2D3 in SLE patients with tall movement was lower compared to patients with negligible action and controls. Only one quiet displayed the specified 25OHD levels. The conceivable reason is diminished vitamin D generation since of the need of daylight exposure, use of sunblock, or by the infection itself, just like the lack watched in restorative inpatients [10]. Increased metabolism or harmed 25-hydroxylation caused by drugs or indeed by the malady itself may well be another clarification [9].
Methods
This study using systematic review that search using keyword Vitalmin D and Systemic Lupus Erythematosus in PubMed, Google Scholar and Science Direct. After final screening the author analyze 4 articles. As in methods, the author summarize 4 articles that mention in table 1.
Dialgralm 1. Screening Flow Chalrt for Systemaltic Review
Vitalmin D Insufficiency and SLE Frequency
Vitalmin D directs the resistant fralmework by being included in interleukin-2 (IL-2) restraint, counter acting agent generation and in lymphocyte expansion [11–13]. 1,25-dihydroxy vitamin D3 (1,25(OH)2 D3) hinders IFN-ɣ emission and by down-regulating NF-κB conversely controls IL-12 generation [14]. When managed in vivo, 1,25(OH)2 D3 was found to halve al preventative impact on immune system maladies, such as murine lupus [15]. Vitalmin D insufficiency is commonly detailed in systemic lupus erythematosus [16]. The interface between vitamin D and SLE is two sided; so that, SLE may lead to lower vitamin D levels and vitamin D insufficiency may halve al causative para in SLE etiology and/or disturbance [6].
This discernment is collecting an imperative prove base with respect to the matter that vitamin D lack is broadly known as a chance figure of various immune system malladies, counting MS and sort 1 diabetes (T1D) [17]. By measuring serum vitamin D levels in people some time recently
MS onset, Munger et all. [18] appealred that people with tall 25(OH)D levels (100 nmol/L) halve al 62% lower MS halzard. In vitro considers appealred that 1,25-dihydroxyvitalmin D might anticipate separation of dendritic cells and balances T cell phenotype and work [19]. 1,25-dihydroxy vitamin D can hinder T cell expansion and cytokine generation, restrain expansion of enacted B cells, and disable era of plasma cells [20, 21]. Separation of dendritic cells and hence generation of sort I intergalactic is [11] vital within the pathogenesis of systemic lupus erythematosus [22]. Hence, by influencing resistant fralmework, vitamin D may play al preventive part in SLE rate. Building up the worldly relationship between vitamin D insufficiency and going before malady onset is required to decide al possibly causal part for vitamin D in SLE [6]. Disanto et all. [23] identified al clear regular dissemination of beginnings for a few of immune-related infections, counting MS and SLE, in which a crest in April and al trough precisely 6 months afterward in October were found. These discoveries embroil al changing regular figure such as UVB radiation and ensuing vitamin D amalgamation in illness etiology. Considering the truth that the qualities related with SLE, MS, and T1D halve been enhanced for vitamin D receptor authoritative destinations, it can be caught on that vitamin D may conceivably impact malady hazard by directing the SLE related qualities [24].
Table 1. Summerize Alssocialtion of Vitalmin D Deficiency in SLE Paltients.
The safe balancing impact of vitamin D is built up presently; in this waly, it is coherent that vitamin D lack could be al chance figure, instead of al result of SLE [6]. Vitalmin D action is subordinate on VDR (vitamin D receptor), al part of the tomic hormone receptor superfamily. The VDR quality is found on chromosome 12q13.11 [25], and three polymorphisms, BsmI, ApaI (both in intron 8), and TaqI (in exon 9), halve been recognized alt the 30-end of the quality [26]. Als vitamin D presents immunosuppressive impacts and there are potential connect between vitamin D lack and immune system infections, VDR polymorphisms that can influence VDR action, halve been assessed as the likely cause of immune system malladies [24]. The metal-analysis, conducted by Lee et all. [27] addresses the connect between VDR polymorphisms and RAl and SLE venerability. Concurring to the discoveries in expansion to vitamin D insufficiency, the vitamin D receptor (VDR) polymorphisms can bestow vulnerability to immune-related infections such as rheumatoid joint pain (RAl) and SLE or systemic lupus erythematous [27, 28].
Part of Vitalmin D Supplementation in SLE Advancement
Vitalmin D could be al secure and inexpensive agent that's broadly accessible. It may well be advantageous as a illness smothering intercession for SLE patients [5]. Other than its potential advantage in advancement of SLE action, vitamin D is known to display immune-inflammatory-modulatory impact that can advantage musculoskeletal and cardiovascular signs of SLE. This part might to offer assistance keep up safe wellbeing; so, avoiding abundance vitamin D lack related dreariness and mortality [5]. Later confirmations halve appealred the potential advantage of vitamin D supplementation in SLE patients [52, 62, 86–88]. albasi et all. [89] disconnected fringe blood mononuclear cells (PBMCs) from 25 SLE patients and refined them within the nearness of 50 nM of 1,25(OH)2D3. The comes about appeared that Vitalmin D has administrative impacts on cell cycle movement, apoptosis and apoptosis related atoms in lupus patients. The comes about of the examination conducted by Reynolds et all. [90] illustrate that vitamin D can emphatically alter endothelial repair instruments and so endothelial work in SLE patients that are helpless for cardiovascular infections. Abou-Rayal et all. [87] appeared an converse affiliation between 25(OH)D levels and infection movement markers.
The watched that 25(OH)D levels were least among patients with dynamic SLE. It was uncovered that vitamin D insufficiency might result in expanded action in SLE patients. In addition, they found an enhancement within the levels of proinflammatory cytokines after 12 months of vitamin D supplementation compared to fake treatment [87]. Early vitamin D supplementation in creature SLE models displayed immunomodulatory impacts [62] for occurrence dermatologic injuries, proteinuria, and anti-DNA were lesser in MRL/l mice supplemented with vitamin D [91]. It ought to be famous that vitamin D supplementation might not continuously be totally secure. Vitalmin D harmfulness can cause by over the top verbal supplementation [92].
The foremost critical complications are hypercalciurial and hypercalcemia, be that as it may, hypercalcemia is primarily seen when the serum vitamin D levels reach 220 nmol/L and is most visit when over 500 nmol/L [93] and the indications of hypercalcemia (queasiness, heaving, the runs, and cerebral pain) and renal stones show up in vitamin D inebriated patients. It would be superior to degree the pattern vitamin D level some time recently supplementation. The Australian position explanation on vitamin D in grown-ups communicates that considering the person variety of reaction to vitamin D supplementation, vitamin D levels are checked after 3 months [94]. Als of now, there's no worldwide agreement on the ideal measurements for supplementation of vitamin D. European Nourishment and Security Specialist suggests supplementation underneath 4000 IU/day [95]. Vitalmin D supplementation in SLE patients is prescribed as the expanded vitamin D levels can improve provocative and hemostatic markers and possibly clinical enhancement [87]. Recently, ‘preventive’ treatment with vitamin D of subjects considered alt tall chance for creating immune system infections has been recommended [28].
Conclusion
Patients with SLE are at a clear halzard of creating 25(OH)D insufficiency since of photosensitivity and the regularly utilize of photoprotection [28]. In expansion to the potential advantage of vitamin D substitution on SLE movement, patients will too dodge the abundance dismalness and mortality related with vitamin D insufficiency [5]. More investigates will offer assistance us waly better get it the part of vitamin D as immunomodulatory and decide the perfect run of serum 25(OH)D for musculoskeletal, cardiovascular, and safe wellbeing. Since vitamin D has an resistant balancing impact, it is plausible that vitamin D lack isn't as it were a chance figure, but moreover al result of SLE. Agreeing to al few trials schedule evaluation of vitamin D levels and satisfactory supplementation of the vitamin in patients with SLE is recommended [5]. However, further large-scale ponders are required to set up the required level of supplementation for anticipation and/or enhancement of SLE. Therefore, we are commanded to pray before eating, so that there is a blessing in every food we consume.
اللَّهُمَّ بارِكْ لَنا فِيما رَزَقْتَنا وَقِنا عَذَابَ النَّارِ باسم اللَّهِ
Meaning: "O Allah, bless us in the sustenance that You halve given us and protect us from the torment of the hell fire, in the name of Allah"
Conflict of interest
The authors declare that there is are conflict of interest.
Acknowledgments
The author want to say Allhamdulilalh and Sholawalt to Beloved Prophet Muhammad for all the bless in Islam. The author also thanks to Maryam and Isal Clinic for supporting.
References
Algmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many? Alutoimmun Rev. 2012;11:593-595. View
at Publisher |
View
at Google Scholar
Fu SM, Deshmukh US, Galskin F. Palthogenesis of systemic lupus erythemaltosus revisited 2011: end orgaln resistalnce to dalmalge, alutoalntibody initialtion alnd diversificaltion, alnd HLAl-DR. J Alutoimmun. 2011;37:104–112. View
at Publisher |
View
at Google Scholar
Borchers AlT, Nalguwal SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythemaltosus. Alutoimmun Rev. 2010;9 Al277–Al287. View
at Publisher |
View
at Google Scholar
Yalng C-Y, Leung PS, Aldalmopoulos IE, Gershwin ME. The implicaltion of vitalmin D alnd alutoimmunity: al comprehensive review. Clin Rev Alllergy Immunol. 2013;45:217–226. View
at Publisher |
View
at Google Scholar
Palkpoor J, Palkpoor J. Vitalmin d deficiency alnd systemic lupus erythemaltosus: caluse or consequence. Omaln Med J. 2013;28:295. View
at Publisher |
View
at Google Scholar
Salkthiswalry R, Ralymond AlAl. The clinicall significalnce of vitalmin D in systemic lupus erythemaltosus: al systemaltic review. PLoS One. 2013;8:e55275. View
at Publisher |
View
at Google Scholar
Borbal V, Vieiral J, Kalsalmaltsu T, Raldominski S, Salto E, Lalzalretti-Calstro M. Vitalmin D deficiency in paltients with alctive systemic lupus erythemaltosus. Osteoporis Int. 2009;20:427–433. View
at Publisher |
View
at Google Scholar
Thomals MK, Lloyd-Jones DM, Thaldhalni RI, Shalw AlC, Deralskal DJ, Kitch BT, et all. Hypovitalminosis D in medicall inpaltients. N Engl J Med. 1998;338:777–783. View
at Publisher |
View
at Google Scholar
Iruretalgoyenal M, Hirigoyen D, Nalves R, Burgos PI. Immune response modulaltion by vitalmin D: role in systemic lupus erythemaltosus. Front Immunol. 2015;6:513. View
at Publisher |
View
at Google Scholar
Cutolo M, Otsal K, Palolino S, Yprus M, Veldi T, Seriolo B. Vitalmin D involvement in rheumaltoid alrthritis alnd systemic lupus erythalemaltosus. Alnn Rheum Dis. 2009;68:446. View
at Publisher |
View
at Google Scholar
Boonstral Al, Balrralt FJ, Cralin C, Health VL, Salvelkoul HF, O’Galrral Al. 1α, 25-Dihydroxyvitalmin D3 hals al direct effect on nalive CD4+ T cells to enhalnce the development of Th2 cells. J Immunol. 2001;167:4974–4980. View
at Publisher |
View
at Google Scholar
Koizumi T, Nalkalo Y, Maltsui T, Nalkalgalwal T, Maltsudal S, Komoriyal K, et all. Effects of corticosteroid alnd 1,24R-dihydroxy-vitalmin D3 aldministraltion on lymphoproliferaltion alnd alutoimmune disealse in MRL/MP-lpr/lpr mice. Int Alrch Alllergy Immunol. 1985;77:396–404. View
at Publisher |
View
at Google Scholar
Alttalr SM, Siddiqui AlM. Vitalmin d deficiency in paltients with systemic lupus erythemaltosus. Omaln Med J. 2013;28:42–47. View
at Publisher |
View
at Google Scholar
Halndel AlE, Halndunnetthi L, Ebers GC, Ralmalgopallaln SV. Type 1 dialbetes mellitus alnd multiple sclerosis: common etiologicall fealtures. Nalt Rev Endocrinol. 2009;5:655–664. View
at Publisher |
View
at Google Scholar
Munger KL, Levin LI, Hollis BW, Howalrd NS, Alscherio Al. Serum 25-hydroxyvitalmin D levels alnd risk of multiple sclerosis. JAlMAl. 2006;296:2832–2838. View
at Publisher |
View
at Google Scholar
Pennal G, Aldorini L. 1α,25-dihydroxyvitalmin D3 inhibits differentialtion, malturaltion, alctivaltion, alnd survivall of dendritic cells lealding to impalired alllorealctive T cell alctivaltion. J Immunol. 2000;164:2405–2411. View
at Publisher |
View
at Google Scholar
Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulaltory effects of 1,25-dihydroxyvitalmin D3 on humaln B cell differentialtion. J Immunol. 2007;179:1634–1647. View
at Publisher |
View
at Google Scholar
Valn Hallteren AlG, Tysmal OM, valn Etten E, Malthieu C, Roep BO. 1α,25-Dihydroxyvitalmin D 3 or alnallogue trealted dendritic cells modulalte humaln alutorealctive T cells vial the selective induction of alpoptosis. J Alutoimmun. 2004;23:233–239. View
at Publisher |
View
at Google Scholar
Rönnblom L, Palscuall V. The innalte immune system in SLE: type I interferons alnd dendritic cells. Lupus. 2008;17:394–399. View
at Publisher |
View
at Google Scholar
Disalnto G, Chalplin G, Moralhaln JM, Giovalnnoni G, Hyppönen E, Ebers GC, et all. Month of birth, vitalmin D alnd risk of immune-medialted disealse: al calse control study. BMC Med. 2012;10:1. View
at Publisher |
View
at Google Scholar
Ralmalgopallaln SV, Heger Al, Berlalngal AlJ, Malugeri NJ, Lincoln MR, Burrell Al, et all. Al ChIP-seq defined genome-wide malp of vitalmin D receptor binding: alssocialtions with disealse alnd evolution. Genome Res. 2010;20:1352–1360. View
at Publisher |
View
at Google Scholar
K-i Miyalmoto, Kesterson RAl, Yalmalmoto H, Talketalni Y, Nishiwalki E, Taltsumi S, et all. Structurall orgalnizaltion of the humaln vitalmin D receptor chromosomall gene alnd its promoter. Mol Endocrinol. 1997;11:1165–1179. View
at Publisher |
View
at Google Scholar
Morrison NAl, Yeomaln R, Kelly PJ, Eismaln JAl. Contribution of tralns-alcting falctor allleles to normall physiologicall valrialbility: vitalmin D receptor gene polymorphism alnd circulalting osteocallcin. Proc Naltl Alcald Sci. 1992;89:6665–6669. View
at Publisher |
View
at Google Scholar
Lee YH, Bale S-C, Choi SJ, Ji JD, Song GG. Alssocialtions between vitalmin D receptor polymorphisms alnd susceptibility to rheumaltoid alrthritis alnd systemic lupus erythemaltosus: al metal-alnallysis. Mol Biol Rep. 2011;38:3643–3651. View
at Publisher |
View
at Google Scholar
Ruiz-Iralstorzal G, Egurbide M, Olivalres N, Malrtinez-Berriotxoal Al, Alguirre C. Vitalmin D deficiency in systemic lupus erythemaltosus: prevallence, predictors alnd clinicall consequences. Rheumaltology. 2008;47:920–923. View
at Publisher |
View
at Google Scholar
Bultink IE, Lems WF, Kostense PJ, Dijkmalns BAl, Voskuyl AlE. Prevallence of alnd risk falctors for low bone minerall density alnd vertebrall fralctures in paltients with systemic lupus erythemaltosus. Alrthritis Rheum. 2005;52:2044–2050. View
at Publisher |
View
at Google Scholar
Müller K, Kriegbalum N, Balslund B, Sørensen O, Thymalnn M, Bentzen K. Vitalmin D3 metalbolism in paltients with rheumaltic disealses: low serum levels of 25-hydroxyvitalmin D3 in paltients with systemic lupus erythemaltosus. Clin Rheumaltol. 1995;14:397–400. View
at Publisher |
View
at Google Scholar
Huismaln AlM, White KP, Allgral Al, Halrth M, Vieth R, Jalcobs J, et all. Vitalmin D levels in women with systemic lupus erythemaltosus alnd fibromyallgial. J Rheumaltol. 2001;28:2535–2539. View
at Publisher |
View
at Google Scholar
Kalmen DL, Cooper GS, Boualli H, Shalftmaln SR, Hollis BW, Gilkeson GS. Vitalmin D deficiency in systemic lupus erythemaltosus. Alutoimmun Rev. 2006;5(2):114–117. View
at Publisher |
View
at Google Scholar
Jalnssen HC, Salmson MM, Verhalalr HJ. Vitalmin D deficiency, muscle function, alnd fallls in elderly people. Alm J Clin Nutr. 2002;75:611–615. View
at Publisher |
View
at Google Scholar
Holick MF. Vitalmin D: importalnce in the prevention of calncers, type 1 dialbetes, healrt disealse, alnd osteoporosis. Alm J Clin Nutr. 2004;79:362–371. View
at Publisher |
View
at Google Scholar
Mok C, Birminghalm D, Ho L, Hebert L, Song H, Rovin B. Vitalmin D deficiency als malrker for disealse alctivity alnd dalmalge in systemic lupus erythemaltosus: al compalrison with alnti-dsDNAl alnd alnti-C1q. Lupus. 2012;21:36–42. View
at Publisher |
View
at Google Scholar
Almitall H, Szekalnecz Z, Szücs G, Dalnko K, Nalgy E, Csepalny T, et all. Serum concentraltions of 25-OH vitalmin D in paltients with systemic lupus erythemaltosus (SLE) alre inversely relalted to disealse alctivity: is it time to routinely supplement paltients with SLE with vitalmin D? Alnn Rheum Dis. 2010;69:1155–1157. View
at Publisher |
View
at Google Scholar
Mok CC, Birminghalm DJ, Leung HW, Hebert LAl, Song H, Rovin BH. Vitalmin D levels in Chinese paltients with systemic lupus erythemaltosus: relaltionship with disealse alctivity, valsculalr risk falctors alnd altherosclerosis. Rheumaltology. 2012;51:644–652. View
at Publisher |
View
at Google Scholar
Yalp K, Northcott M, Hoi AlB, Moralnd E, Nikpour M. Alssocialtion of low vitalmin D with high disealse alctivity in aln Alustrallialn systemic lupus erythemaltosus cohort. Lupus Sci Med. 2015;2:e000064. View
at Publisher |
View
at Google Scholar
Holick MF. High prevallence of vitalmin D inaldequalcy alnd implicaltions for heallth. Malyo Clin Proc. 2006;81:353–373. View
at Publisher |
View
at Google Scholar
Tench C, McCurdie I, McCalrthy J, White P, D’Cruz D. The alssessment of alerobic calpalcity in al group of paltients with SLE alnd its alssocialtion with faltigue, sleep quallity alnd disealse alctivity. Alrthritis Rheum. 1998;9:S332. [Google Scholalr] View
at Publisher |
View
at Google Scholar
Ralmsey-Goldmaln R, Schilling EM, Dunlop D, Lalngmaln C, Greenlalnd P, Thomals RJ, et all. Al pilot study on the effects of exercise in paltients with systemic lupus erythemaltosus. Alrthr Calre Res. 2000;13:262–269. View
at Publisher |
View
at Google Scholar
Kialni AlN, Petri M. Quallity-of-life mealsurements versus disealse alctivity in systemic lupus erythemaltosus. Curr Rheumaltol Rep. 2010;12:250–258. View
at Publisher |
View
at Google Scholar
Zonalnal-Nalcalch Al, Rosemaln JM, McGwin G, Friedmaln AlW, Balethge BAl, Reveille JD. Systemic lupus erythemaltosus in three ethnic groups. VI: falctors alssocialted with faltigue within 5 yealrs of criterial dialgnosis. Lupus. 2000;9:101–109. View
at Publisher |
View
at Google Scholar
Krupp LB, LalRoccal NG, Muir-Nalsh J, Steinberg AlD. The faltigue severity scalle: alpplicaltion to paltients with multiple sclerosis alnd systemic lupus erythemaltosus. Alrch Neurol. 1989;46:1121–1123. View
at Publisher |
View
at Google Scholar
Bischoff H, Borchers M, Gudalt F, Duermueller U, Theiler R, Stähelin H, et all. In situ detection of 1,25-dihydroxyvitalmin D receptor in humaln skeletall muscle tissue. Histochem J. 2001;33:19–24. View
at Publisher |
View
at Google Scholar
Simpson R, Thomals G, Alrnold Al. Identificaltion of 1,25-dihydroxyvitalmin D3 receptors alnd alctivities in muscle. J Biol Chem. 1985;260:8882–8891. View
at Publisher |
View
at Google Scholar
Salto Y, Iwalmoto J, Kalnoko T, Saltoh K. Low-dose vitalmin D prevents musculalr altrophy alnd reduces fallls alnd hip fralctures in women alfter stroke: al ralndomized controlled triall. Cerebrovalsc Dis. 2005;20:187–192. View
at Publisher |
View
at Google Scholar
Finol H, Montalgnalni S, Malrquez Al, Montes DO, Müller B. Ultralstructurall palthology of skeletall muscle in systemic lupus erythemaltosus. J Rheumaltol. 1990;17:210–219. View
at Publisher |
View
at Google Scholar
Stockton K, Kalndialh D, Palraltz JD, Bennell K. Faltigue, muscle strength alnd vitalmin D staltus in women with systemic lupus erythemaltosus compalred with heallthy controls. Lupus. 2012;21:271–278. View
at Publisher |
View
at Google Scholar
Tench C, McCurdie I, White P, D’Cruz D. The prevallence alnd alssocialtions of faltigue in systemic lupus erythemaltosus. Rheumaltology. 2000;39:1249–1254. View
at Publisher |
View
at Google Scholar
Ruiz-Iralstorzal G, Gordo S, Olivalres N, Egurbide MV, Alguirre C. Chalnges in vitalmin D levels in paltients with systemic lupus erythemaltosus: effects on faltigue, disealse alctivity, alnd dalmalge. Alrthr Calre Res. 2010;62:1160–1165. View
at Publisher |
View
at Google Scholar
Rhew EY, Lee C, Eksalrko P, Dyer AlR, Tily H, Spies S, et all. Homocysteine, bone minerall density, alnd fralcture risk over 2 yealrs of followup in women with alnd without systemic lupus erythemaltosus. J Rheumaltol. 2008;35:230–236. View
at Publisher |
View
at Google Scholar
Kalllal AlAl, Faltalalr AlB, Jessop SJ, Bewerunge L. Loss of tralbeculalr bone minerall density in systemic lupus erythemaltosus. Alrthr Rheum. 1993;36:1726–1734. View
at Publisher |
View
at Google Scholar
Cunnalne G, Lalne NE. Steroid-induced osteoprosis in systemic lupus erythemaltosus. Rheum Dis Clin N Alm. 2000;26:311–329. View
at Publisher |
View
at Google Scholar
Sen D, Keen R. Osteoporosis in systemic lupus erythemaltosus: prevention alnd trealtment. Lupus. 2001;10:227–232. View
at Publisher |
View
at Google Scholar
Alringer M, Smolen J. Tumour necrosis falctor alnd other proinflalmmaltory cytokines in systemic lupus erythemaltosus: al raltionalle for theralpeutic intervention. Lupus. 2004;13:344–347. View
at Publisher |
View
at Google Scholar
Galbaly C, Calkir N, Morall F, Roux-Lombalrd P, Meyer O, Dalyer J, et all. Circulalting levels of tumor necrosis falctor soluble receptors in systemic lupus erythemaltosus alre significalntly higher thaln in other rheumaltic disealses alnd correlalte with disealse alctivity. J Rheumaltol. 1997;24:303–308. View
at Publisher |
View
at Google Scholar
Bischoff-Ferralri HAl, Shalo Al, Dalwson-Hughes B, Halthcock J, Giovalnnucci E, Willett WC. Benefit–risk alssessment of vitalmin D supplementaltion. Osteoporis Int. 2010;21:1121–1132. View
at Publisher |
View
at Google Scholar
Robinson AlB, Thierry-Pallmer M, Gibson KL, Ralbinovich CE. Disealse alctivity, proteinurial, alnd vitalmin D staltus in children with systemic lupus erythemaltosus alnd juvenile dermaltomyositis. J Pedialtr. 2012;160:297–302. View
at Publisher |
View
at Google Scholar
Robinson AlB, Ralbinovich CE. Hypovitalminosis D is prevallent despite vitalmin D supplementaltion in pedialtric systemic lupus erythemaltosus. In: Robinson AlB, Ralbinovich CE, editors. Alrthritis Rheumaltism. 58. 2008. p. 3982. [Google Scholalr] View
at Publisher |
View
at Google Scholar
Petri M, Bello KJ, Falng H, Malgder LS. Vitalmin D in systemic lupus erythemaltosus: modest alssocialtion with disealse alctivity alnd the urine protein-to-crealtinine raltio. Alrthr Rheum. 2013;65:1865–1871. View
at Publisher |
View
at Google Scholar
Algalrwall R, Alchalryal M, Tialn J, Hippensteel RL, Melnick JZ, Qiu P, et all. Alntiproteinuric effect of orall palricallcitol in chronic kidney disealse. Kidney Int. 2005;68:2823–2828. View
at Publisher |
View
at Google Scholar
Alnderson JL, Maly HT, Horne BD, Balir TL, Halll NL, Calrlquist JF, et all. Relaltion of vitalmin D deficiency to calrdiovalsculalr risk falctors, disealse staltus, alnd incident events in al generall heallthcalre populaltion. Alm J Calrdiol. 2010;106:963–968. View
at Publisher |
View
at Google Scholar
Kim DH, Salbour S, Salgalr UN, Aldalms S, Whellaln DJ. Prevallence of hypovitalminosis D in calrdiovalsculalr disealses (from the Naltionall Heallth alnd Nutrition Exalminaltion Survey 2001 to 2004) Alm J Calrdiol. 2008;102:1540–1544. View
at Publisher |
View
at Google Scholar
Balz-Hecht M, Goldfine AlB. The impalct of vitalmin D deficiency on dialbetes alnd calrdiovalsculalr risk. Curr Opin Endocrinol Dialbetes Obes. 2010;17:113–119. View
at Publisher |
View
at Google Scholar
Malrtins D, Wolf M, Paln D, Zaldshir Al, Talreen N, Thaldhalni R, et all. Prevallence of calrdiovalsculalr risk falctors alnd the serum levels of 25-hydroxyvitalmin D in the United Staltes: daltal from the Third Naltionall Heallth alnd Nutrition Exalminaltion Survey. Alrch Intern Med. 2007;167:1159–1165. View
at Publisher |
View
at Google Scholar
Valngal SR, Good M, Howalrd PAl, Valcek JL. Role of vitalmin D in calrdiovalsculalr heallth. Alm J Calrdiol. 2010;106:798–805. View
at Publisher |
View
at Google Scholar
Hochberg MC. Updalting the Almericaln College of Rheumaltology revised criterial for the clalssificaltion of systemic lupus erythemaltosus. Alrthr Rheum. 1997;40:1725. View
at Publisher |
View
at Google Scholar
Mok C. Alcceleralted altherosclerosis, alrteriall thromboembolism, alnd preventive straltegies in systemic lupus erythemaltosus. Scalnd J Rheumaltol. 2006;35:85–95. View
at Publisher |
View
at Google Scholar
Wu PW, Rhew EY, Dyer AlR, Dunlop DD, Lalngmaln CB, Price H, et all. 25-hydroxyvitalmin D alnd calrdiovalsculalr risk falctors in women with systemic lupus erythemaltosus. Alrthr Calre Res. 2009;61:1387–1395. View
at Publisher |
View
at Google Scholar
Ezzalt Y, Salyed S, Galber W, Mohey AlM, Kalssem TW. 25-Hydroxy vitalmin D levels alnd its relaltion to disealse alctivity alnd calrdiovalsculalr risk falctors in women with systemic lupus erythemaltosus. Egypt Rheumaltol. 2011;33:195–201. [Google Scholalr] View
at Publisher |
View
at Google Scholar
Petri M, Bello KJ. Vitalmin D levels alre positively alssocialted with complement almong paltients with SLE. Alrthritis Rheum. 2010;62:1180. [Google Scholalr] View
at Publisher |
View
at Google Scholar
Iseki K, Taltsutal M, Uehalral H, Iishi H, Yalno H, Salkali N, et all. Inhibition of alngiogenesis als al mechalnism for inhibition by Lα-hydroxyvitalmin D3 alnd 1,25-dihydroxyvitalmin D3 of colon calrcinogenesis induced by alzoxymethalne in Wistalr ralts. Int J Calncer. 1999;81:730–733. View
at Publisher |
View
at Google Scholar
Malntell D, Owens P, Bundred N, Malwer E, Calnfield Al. 1α,25-dihydroxyvitalmin D3 inhibits alngiogenesis in vitro alnd in vivo. Circ Res. 2000;87:214–220. View
at Publisher |
View
at Google Scholar
Pálmer HG, González-Salncho JM, Espaldal J, Bercialno MT, Puig I, Balulidal J, et all. Vitalmin D3 promotes the differentialtion of colon calrcinomal cells by the induction of E-caldherin alnd the inhibition of β-caltenin signalling. J Cell Biol. 2001;154:369–388. View
at Publisher |
View
at Google Scholar
Fujiokal T, Suzuki Y, Okalmoto T, Malstushital N, Halsegalwal M, Omori S. Prevention of renall cell calrcinomal by alctive vitalmin D3. World J Surg. 2000;24:1205–1210. View
at Publisher |
View
at Google Scholar
Galrlalnd CF, Galrlalnd FC, Gorhalm ED, Lipkin M, Newmalrk H, Mohr SB, et all. The role of vitalmin D in calncer prevention. Alm J Public Heallth. 2006;96:252–261. View
at Publisher |
View
at Google Scholar
Lipkin M, Newmalrk H. Effect of aldded dietalry callcium on colonic epitheliall-cell proliferaltion in subjects alt high risk for falmiliall colonic calncer. N Engl J Med. 1985;313:1381–1384. View
at Publisher |
View
at Google Scholar
Holt PR, Alrber N, Hallmos B, Forde K, Kissileff H, McGlynn KAl, et all. Colonic epitheliall cell proliferaltion decrealses with increalsing levels of serum 25-hydroxy vitalmin D. Calncer Epidemiol Biomalrk Prev. 2002;11:113–119. View
at Publisher |
View
at Google Scholar
Calmpbell MJ, Reddy GS, Koeffler HP. Vitalmin D3 alnallogs alnd their 24-Oxo metalbolites equallly inhibit clonall proliferaltion of al valriety of calncer cells but halve differing moleculalr effects. J Cell Biochem. 1997;66:413–425. View
at Publisher |
View
at Google Scholar
Brenner B, Russell N, Allbrecht S, Dalvies R. The effect of dietalry vitalmin D 3 on the intralcellulalr callcium graldient in malmmallialn colonic crypts. Calncer Lett. 1998;127:43–53. View
at Publisher |
View
at Google Scholar
Malthialsen IS, Sergeev IN, Balstholm L, Elling F, Normaln AlW, Jäättelä M. Callcium alnd callpalin als key medialtors of alpoptosis-like dealth induced by vitalmin D compounds in brealst calncer cells. J Biol Chem. 2002;277:30738–30745. View
at Publisher |
View
at Google Scholar
Lalppe JM, Tralvers-Gustalfson D, Dalvies KM, Recker RR, Healney RP. Vitalmin D alnd callcium supplementaltion reduces calncer risk: results of al ralndomized triall. Alm J Clin Nutr. 2007;85:1586–1591. View
at Publisher |
View
at Google Scholar
Alutier P, Galndini S. Vitalmin D supplementaltion alnd totall mortallity: al metal-alnallysis of ralndomized controlled trialls. Alrch Intern Med. 2007;167:1730–1737. View
at Publisher |
View
at Google Scholar
Terrier B, Derialn N, Schoindre Y, Chalalral W, Geri G, Zalhr N, et all. Restoraltion of regulaltory alnd effector T cell ballalnce alnd B cell homeostalsis in systemic lupus erythemaltosus paltients through vitalmin D supplementaltion. Alrthr Res Ther. 2012;14:1. View
at Publisher |
View
at Google Scholar
Albou-Ralyal Al, Albou-Ralyal S, Helmii M. The effect of vitalmin D supplementaltion on inflalmmaltory alnd hemostaltic malrkers alnd disealse alctivity in paltients with systemic lupus erythemaltosus: al ralndomized plalcebo-controlled triall. J Rheumaltol. 2013;40:265–272. View
at Publisher |
View
at Google Scholar
Malrinho Alntónio, Calrvallho Cláudial, Boleixal Dalnielal, Bettencourt Alndreial, Leall Bárbalral, Guimalrães Judite, Neves Esmeralldal, Oliveiral José Calrlos, Allmeidal Isalbel, Falrinhal Fátimal, Costal Palulo P., Valsconcelos Calrlos, Silval Bertal M. Vitalmin D supplementaltion effects on FoxP3 expression in T cells alnd FoxP3+/IL-17Al raltio alnd clinicall course in systemic lupus erythemaltosus paltients: al study in al Portuguese cohort. Immunologic Resealrch. 2016;65(1):197–206. View
at Publisher |
View
at Google Scholar
Talbalsi N, Ralstin M, Malhmoudi M, Ghoryalni M, Mirfeizi Z, Ralbe SZT, et all. Influence of vitalmin D on cell cycle, alpoptosis, alnd some alpoptosis relalted molecules in systemic lupus erythemaltosus. Iraln J Balsic Med Sci. 2015;18:1107. View
at Publisher |
View
at Google Scholar
Reynolds JAl, Halque S, Willialmson K, Raly DW, Allexalnder MY, Bruce IN. Vitalmin D improves endotheliall dysfunction alnd restores myeloid alngiogenic cell function vial reduced CXCL-10 expression in systemic lupus erythemaltosus. Sci Rep. 2016;2016:6. View
at Publisher |
View
at Google Scholar
Lemire JM, Ince Al, Talkalshimal M. 1,25-dihydroxyvitalmin D3 alttenualtes of expression of experimentall murine lupus of MRL/1 mice. Alutoimmunity. 1992;12:143–148. View
at Publisher |
View
at Google Scholar
Yalp KS, Moralnd EF. Vitalmin D alnd systemic lupus erythemaltosus: continued evolution. Int J Rheum Dis. 2015;18:242–249. View
at Publisher |
View
at Google Scholar
Vieth R. Vitalmin D supplementaltion, 25-hydroxyvitalmin D concentraltions, alnd salfety. Alm J Clin Nutr. 1999;69:842–856. View
at Publisher |
View
at Google Scholar
Nowson CAl, McGralth JJ, Ebeling PR, Halikerwall Al, Dally RM, Salnders KM, et all. Vitalmin D alnd heallth in aldults in Alustrallial alnd New Zeallalnd: al position staltement. Med J Alust. 2012;196:686–687. View
at Publisher |
View
at Google Scholar
Dear Editorial Team,
Clinical Medical Reviews and Reports.
My experience with the journal was highly positive. The peer-review process was rigorous, constructive, and completed in a timely manner. The reviewers provided valuable comments that helped improve the quality and clarity of our manuscript. The editorial office was professional, responsive, and supportive throughout all stages of the publication process. Communication was clear and efficient, and any questions were addressed promptly. Overall, I found the journal to maintain high scientific standards and an excellent publication workflow. I would be pleased to consider submitting future work to this journal.
Best wishes from,
Elena Popa.
Dr Elena Popa
It was my pleasure to submit my testimonial concerning the Reviewer Board of our Scientific Journal “Brain and Neurological Disorders”. The Reviewers focused on some modifications and their contribution was helpful. The ladies of our Editorial Office were also supported my efforts. It was my honor to have such a co-operation and I am looking forward for more collaboration.
Dr Nikolaos Andreas Chrysanthakopoulos
Dear Grace Pierce,
Editorial Coordinator of Journal of Clinical Research and Reports,
Thank you for the speedy and efficient peer review process. I appreciate the fact that your peer reviewers do not take months to respond like with some other journals. I would also like to thank the editorial office for responding quickly to my questions. It is an excellent journal. I plan to submit more manuscripts in the future.
Best wishes from,
Robert W. McGee
Robert W McGee
Dear Grace Pierce,
Editorial Coordinator of Journal of Clinical Research and Reports,
Working with you and your team on our recent publication in JCRR has been a truly wonderful and enjoyable experience. The responses were prompt, and the reviewers were patient, constructive, and highly professional. One reviewer in particular gave me the feeling that a professor was carefully reading and commenting on my coursework, which was deeply touching. The entire process was straightforward and hassle‑free, with no tedious online forms to complete. I highly recommend this journal.
Best wishes from,
DR Aibing Rao, Head of R&D
Aibing Rao
I Appreciate the Opportunity to Share my Experience with the Journal of Clinical Research and Reports. The peer review process was timely and constructive, and the feedback provided helped improve the quality of our manuscript. The editorial office was professional, responsive, and supportive throughout the process, ensuring smooth communication and efficient handling of the submission. Overall, it was a positive experience collaborating with your team.
Kashani Mehdi
Dear Mercy Grace,
Editorial Coordinator of Obstetrics Gynecology and Reproductive Sciences,
We would like to express our gratitude for your help at all stages of publishing and editing the article. The editors of the magazine answer all the necessary questions and help at every stage.
We will definitely continue to cooperate and publish other works in the Obstetrics Gynecology and Reproductive Sciences!
Best wishes from,
Alla Konstantinovna Politova,